[an error occurred while processing this directive]
中华放射肿瘤学杂志
   2025年4月7日 星期一     首 页 |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告合作  |  学术影响  |  收录情况  |  联系我们  |  English
中华放射肿瘤学杂志  2022, Vol. 31 Issue (1): 59-64    DOI: 10.3760/cma.j.cn113030-20201206-00589
物理·技术·生物 最新目录| 下期目录| 过刊浏览| 高级检索 [an error occurred while processing this directive]|[an error occurred while processing this directive]
形变配准在螺旋断层治疗联合近距离治疗宫颈癌剂量叠加中的应用
王为, 周晴, 蒋马伟
上海交通大学医学院附属新华医院肿瘤科,上海 200092
Application of deformable image registration in radiotherapy dose accumulation of helical tomotherapy combined with brachytherapy for cervical cancer
Wang Wei, Zhou Qing, Jiang Mawei
Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      背景资料
摘要 目的 探讨形变配准在螺旋断层(HT)调强联合高剂量率近距离治疗的宫颈癌放疗中评估膀胱直肠受量的可行性。方法 对18例宫颈癌患者回顾分析,比较直肠和膀胱D2cm3及高危临床靶区(HR-CTV) D90%的二维参数相加的均匀剂量法(EUD)和高剂量重叠法(OHD)的受量,以及应用MIM Maestro®软件的刚性图像配准(RIR)和形变图像配准(DIR)受量。用戴斯相似性系数(DSC)和平均一致性距离(MDA)评估配准精度。结果 EUD、OHD、RIR、DIR的膀胱和直肠D2cm3分别为(80.11±3.59)、(82.23±3.46)、(80.99±6.01)、(81.19±3.11)Gy (EQD2Gy)(P=0.516)和(72.90±3.58)、(73.83±4.28)、(72.45±6.05)、(71.98±2.89)Gy (EQD2Gy)(P=0.625),HR-CTV的D90%分别为(85.51±2.91)、(87.65±3.46)、(81.53±3.63)、(85.81±3.30)Gy (EQD2Gy)(P<0.001)。RIR和DIR的膀胱、直肠、HR-CTV的DSC均值分别为0.69、0.65、0.63和0.85、0.81、0.78(P<0.001),DIR的MDA均值分别为2.88、2.48、2.66mm。结论 4种方法膀胱、直肠D2cm3相近,DIR匹配优于RIR (DSC>0.8)。DIR在HT和后装剂量叠加中具一定参考价值。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
王为
周晴
蒋马伟
关键词 形变图像配准剂量评估宫颈肿瘤/近距离疗法宫颈肿瘤/螺旋断层疗法    
AbstractObjective To assess the feasibility of deformable image registration (DIR) in evaluating cumulative dose distribution of bladder and rectum of cervical cancer patients during helical tomotherapy (HT)-based intensity-modulated radiotherapy (IMRT) and high-dose-rate(HDR) brachytherapy. Methods Clinical data of 18 patients were retrospectively analyzed. Cumulative bladder/rectum D2cm3 and high-risk clinical target volume (HR-CTV) D90% parameters were calculated and compared to two direct parameter-adding methods with two registration-adding methods. Equivalent uniform dose (EUD group) and overlapping high dose (OHD group) methods were employed as parameter-adding methods. The registration-adding methods including rigid image registration (RIR group) and deformable image registration (DIR group) were adopted based on a commercial image registration software (MIM Maestro®). The dice similarity coefficient (DSC) and mean distance to agreement (MDA) were measured to assess the accuracy of RIR and DIR. Results In the EUD,OHD,RIR and DIR groups, the cumulative doses of bladder/rectum D2cm3 and HR-CTV D90% were (80.11±3.59)Gy (EQD2Gy),(82.23±3.46)Gy (EQD2Gy),(80.99±6.01)Gy (EQD2Gy) and (81.19±3.11)Gy (EQD2Gy)(P=0.516);(72.90±3.58)Gy (EQD2Gy),(73.83±4.28)Gy (EQD2Gy),(72.45±6.05)Gy (EQD2Gy) and (71.98±2.89)Gy (EQD2Gy)(P=0.625), and (85.51±2.91)Gy (EQD2Gy),(87.65±3.46)Gy (EQD2Gy),(81.53±3.63)Gy (EQD2Gy) and (85.81±3.30)Gy (EQD2Gy)(P<0.001), respectively. The mean DSC of the bladder, rectum and HR-CTV were 0.69, 0.65 and 0.63 with RIR;and 0.85, 0.81 and 0.78 with DIR (P<0.001), respectively. In DIR, the average MDA of bladder, rectum, and HR-CTV were 2.88, 2.48 and 2.66mm, respectively. Conclusions The cumulative DVH parameters among 4 groups show no significant difference in the bladder/rectum D2cm3/D0.2cm3. Since the DIR group achieves satisfactory volume matching of greater than 0.8 with DSC analysis, it can yield acceptable results for clinical application between HT IMRT and HDR BT for cervical cancer.
Key wordsDeformable image registration    Dose evaluation    Cervical neoplasm/brachytherapy    Cervical neoplasm/helical tomotherapy   
收稿日期: 2020-12-06     
通讯作者: 蒋马伟,Email:jiangmawei@xinhuamed.com.cn   
引用本文:   
王为,周晴,蒋马伟. 形变配准在螺旋断层治疗联合近距离治疗宫颈癌剂量叠加中的应用[J]. 中华放射肿瘤学杂志, 2022, 31(1): 59-64.
Wang Wei,Zhou Qing,Jiang Mawei. Application of deformable image registration in radiotherapy dose accumulation of helical tomotherapy combined with brachytherapy for cervical cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(1): 59-64.
链接本文:  
http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20201206-00589     或     http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2022/V31/I1/59
京公网安备11010502022167号
版权所有 © 2010《中华放射肿瘤学杂志》编辑部
地址:北京朝阳区潘学园南里17号 中国医学科学院肿瘤医院(100021)
电话:010-67700737,87788294 Email: cjron@cmaph.org
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:Support@magtech.com.cn